You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, Large B-Cell, Diffuse

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Living Conditions of Diffuse Large B-Cell Lymphoma or Follicular

Completed
  • Diffuse Large Cell Diffuse Lymphoma
  • Follicular Lymphoma
  • Questionnaires
  • Collection of clinical data and treatments
  • Dijon, France
    Chu Dijon Bourogne
Jan 31, 2023

Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Itacitinib
  • Chimeric antigen receptor (CAR) T-cell therapy
  • Tampa, Florida
    Moffitt Cancer Center
Mar 6, 2023

Communication Training Intervention for Large B-Cell Lymphoma

Recruiting
  • Lymphoma, B-Cell
  • +5 more
  • Hematolo-GIST Training
  • Participants Appointment
  • New York, New York
  • +2 more
Jul 3, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone hydrochloride liposome injection
  • +4 more
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Aug 15, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Jan 20, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • maplirpacept (PF-07901801)
  • +2 more
  • (no location specified)
May 30, 2023

DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Lymphoma
  • Other
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Sep 6, 2023

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

Recruiting
  • Diffuse Large B Cell Lymphoma，DLBCL
  • PM 8.4 mg/m2
  • PM 11.2 mg/m2
  • Chengdu, Sichuan, China
    West China Hospital Sichuan University
Jan 15, 2023

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 18, 2023

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

Diffuse Large B Cell Lymphoma Trial in Philadelphia (Nivolumab, IV, 240 mg)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Nivolumab, IV, 240 mg
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jan 3, 2023

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Gut microbiome analysis
  • Bologna, Italy
    Institute Of Hematology "Seràgnoli"
Feb 10, 2023

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023